期刊文献+

血清脂蛋白相关磷脂酶A2及超敏C反应蛋白与急性冠脉综合征的关系 被引量:5

Relationship between lipoprotein associated phospholipase A2 or hs-CRP and acute coronary syndrome
下载PDF
导出
摘要 目的探讨脂蛋白相关磷脂酶(Lp-PL)A2及超敏C反应蛋白(hs-CRP)与急性冠脉综合征(ACS)的发生及冠脉病变严重程度的相关性。方法2017年6月~2018年10月于西安交通大学医学院第一附属医院心脏内科住院并行冠脉造影(CAG)确诊为ACS的患者373例,另外选择同期CAG结果正常的107例患者作为非冠心病组。将ACS患者根据冠脉Gensini积分的中位数进一步分为两组,定义为轻度病变组及重度病变组;根据冠脉病变支数分为三组,分别为单支病变组、双支病变组、三支病变组。结果与非冠心病组相比,ACS组患者的血清Lp-PLA2和炎症指标hs-CRP明显升高,差异均有统计学意义。冠脉重度病变组的血清Lp-PLA2和hs-CRP水平高于冠脉轻度病变组,差异均有统计学意义(P<0.01)。随着冠心病患者病变累及支数的增多,Lp-PLA2水平和Gensini积分也逐渐增加。相关分析显示Lp-PLA2、hs-CRP水平与Gensini积分呈正相关。多因素Logistic回归分析显示,hs-CRP和Lp-PLA2是冠脉病变重度病变的独立危险因素。利用ROC曲线显示Lp-PLA2诊断冠心病的曲线下面积为0.836(95%CI:0.802~0.869)。当Lp-PLA2诊断临界值取129.03 ng/ml时,其诊断效能最高,灵敏度为64.1%,特异度为96.6%。结论血清Lp-PLA2和hs-CRP与ACS冠状动脉病变严重程度成正相关,是冠脉严重病变的独立危险因素。血清Lp-PLA2对ACS有一定的诊断价值。 AIM To investigate the relationship between serum lipoprotein associated phospholipase A2(Lp-PLA2)level or high-sensitivity c-reactive protein(hs-CRP)and the severity of coronary artery stenosis in patients with acute coronary syndrome(ACS).METHODS A total of 480 patients who had undergone coronary angiography in our hospital from June 2017 to October 2018 were enrolled into this study and analyzed retrospectively.Three hundred and seventy-three patients were diagnosed with ACS and they were divided into two groups according to the median of their Gensini score.The two groups were defined as mild lesions group and severe lesions group.Additional 107 non-CAD hospitalized patients were selected as the control group.RESULTS Serum Lp-PLA2 and hs-CRP level in the ACS group were significantly higher than those in the control group and the differences were statistically signi-ficant(P<0.01).Serum Lp-PLA2 and hs-CRP levels in the severe lesion group were higher than those in the mild lesion group and the difference was statistically significant(P<0.01).The serum level of Lp-PLA2 and Gensini score in patients with acute coronary syndrome increased gradually with the increase of the number of lesions and the degree of lesions and the difference was significant(P<0.01).The correlation analysis showed that the levels of serum Lp-PLA2 and hs-CRP were significantly positively correlated with Gensini score.Multivariate logistic regression analysis indicated that the levels of serum Lp-PLA2 and hs-CRP were independent risk factors of ACS.The receiver operating characteristic curve showed that the area under the curve of Lp-PLA2 for the diagnosis of ACS was 0.836(95%CI:0.802~0.869).Lp-PLA2 predicted ACS with a sensitivity of 64.1%and specificity of 96.6%.CONCLUSION The levels of serum Lp-PLA2 and hs-CRP are positively associated with the severity of coronary artery stenosis in ACS patients.The levels of serum Lp-PLA2 and hs-CRP are independent risk factors of severe ACS.Lp-PLA2 has a certain predictive value for ACS.
作者 余航 卢群 高渊 闫斌 田刚 白玲 YU Hang;LU Qun;GAO Yuan;YAN Bin;TIAN Gang;BAI Ling(Department of Cardiology,Xi’an Jiangtong University,Xi’an 710061,Shaanxi,China;Department of Clinical Research Center,First Affiliated Hospital,Xi’an Jiangtong University,Xi’an 710061,Shaanxi,China)
出处 《心脏杂志》 CAS 2020年第3期234-238,256,共6页 Chinese Heart Journal
基金 国家自然科学基金项目资助(81873513)。
关键词 脂蛋白相关磷脂酶A2 超敏C反应蛋白 急性冠脉综合征 lipoprotein associated phospholipase A2 hs-CRP acute coronary syndrome
  • 相关文献

参考文献6

二级参考文献90

  • 1郝恒剑,李耘,李康,魏嘉平,汪家瑞.急性下壁心肌梗死合并完全性房室阻滞患者冠状动脉病变的特点及临床预后[J].中国循环杂志,2004,19(4):255-257. 被引量:2
  • 2刘甲兴,郑兴,秦永文,丁继军,赵仙先,曹江.脂蛋白相关性磷脂酶A_2活性能反映冠状动脉粥样硬化病变程度[J].第二军医大学学报,2006,27(4):391-395. 被引量:31
  • 3柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2146
  • 4洪衡,王明生,王河,李明昌,王磊,肖毅,杨光,王红梅,任海明,贾宁,谭丽玲,顼志敏.不同类型急性心肌梗死冠状动脉病变特点的观察[J].中国循环杂志,2007,22(3):187-190. 被引量:11
  • 5Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25: 923-931.
  • 6Waxman S, Ishibashi F, Muller JE. Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events. Circulation 2006; 114: 2390-2411.
  • 7Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vase Biol 2006; 26: 2523-2529.
  • 8Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14: 1059-1066.
  • 9Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008; 101 (12A): 41F-50E.
  • 10Koenig W, Khuseyinova N. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther 2009; 23: 85-92.

共引文献113

同被引文献60

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部